Medivir AB (LTS:0GP7)
kr 2.73 0 (0%) Market Cap: 302.85 Mil Enterprise Value: 146.87 Mil PE Ratio: 0 PB Ratio: 1.94 GF Score: 58/100

Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call Transcript

Jun 13, 2019 / 08:00AM GMT
Release Date Price: kr19.12
Uli Hacksell;publ;CEO
Medivir AB;President & Director

()- -

Thank you, and good morning, and welcome to today's telephone conference where we will present the study results from the Phase Ia study with MIV-818 in patients with cancer in the liver.

Joining me from Medivir today are Dr. Linda Basse, who is our Chief Medical Officer; Dr. Fredrik Oberg, who is our Director of Preclinical Research; Karin Göhlin, who is Director of Project and Portfolio Management; and Lotta Ferm, who is our Chief Financial Officer. So let's move to Slide #2. I want to start to talk a little bit about cancers in the liver. Let's say first, primary liver cancers compromise a group of very aggressive tumors characterized by large differences in geographical incidence rates. Hepatocellular carcinoma, or HCC, is the third leading cause of cancer-related deaths worldwide. It's an orphan disease in Western markets but still one of the fastest growing and most deadly cancers in the U.S. On the estimated new cases in 2018, around 610,000 are found in Asia; 42,000 in the U.S.; and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot